Neuregulin-1
NRG1proteinNeuregulin-1 activates ERBB2/ERBB4 signaling in endothelial cells, suppressing endothelial-to-mesenchymal transition and stabilizing vascular integrity.
Pathway placement
Cascade stepEndothelial activation & erosion
Confidencemedium
RationaleNRG-1/ERBB signaling suppresses EndMT and protects endothelial barrier.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000157168
Type I vs non-Type I discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I23
C — non-Type-I62
A — assay feasibility68
E — evidence strength23
T1DI (composite)5
Specificity differential (R−C)-38.2
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Tongxinluo Attenuates Myocardiac Fibrosis after Acute Myocardial Infarction in Rats via Inhibition of Endothelial-to-Mesenchymal Transition.BioMed research international · 2019 · PMID 31317035 · doi
Clinical trials(1)
- Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot StudyNCT04391491 · COMPLETED · Neuregulin-1β level in plasma